Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Experimental and Molecular Therapeutics 20: Identification of Molecular Targets 1

A novel small molecule, SR 13179, decreases gelatinase activity in breast carcinoma cells through induction of TIMP-2 protein: A possible mechanism for its anti-invasive and anti-tumor activity

Nahid Waleh, Wan-Ru Chao, Brian Murphy and Nurulain Zaveri
Nahid Waleh
Biosciences Division, SRI International, Menlo Park, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wan-Ru Chao
Biosciences Division, SRI International, Menlo Park, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brian Murphy
Biosciences Division, SRI International, Menlo Park, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nurulain Zaveri
Biosciences Division, SRI International, Menlo Park, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published May 2005
  • Article
  • Info & Metrics
Loading
Proc Amer Assoc Cancer Res, Volume 46, 2005

Abstract

2339

Tissue inhibitor of metalloproteinase-2 (TIMP-2) is known to play a role in the inhibition of tumor invasion and angiogenesis by blocking the activation of pro-MMP-2 (progelatinase) by MT1-MMP, a process regulated by binding of TIMP-2 with MT1-MMP. However, recent data suggest that the antiangiogenic and antitumor effects of TIMP-2 may also occur through MMP-independent mechanisms such as inactivation of some growth signaling pathways. Overexpression of TIMP-2 or adenovirus-mediated TIMP-2 therapy has shown to significantly inhibit tumor growth, angiogenesis and metastasis in animal models. Development of small molecule therapeutic agents that increase cellular TIMP-2 levels therefore offer a new molecular-targeted approach to anti-angiogenic and anti-metastatic treatment of cancer. We report the discovery of a novel class of small molecules, of which SR 13179 is a lead compound, that inhibit the invasion of highly metastatic human breast cancer cell lines MCF10CA1a and MDA-MB-231, at doses that do not affect migration or cell viability. We show that SR 13179 inhibits the gelatinolytic activity of MMP-2 by >50% in zymography experiments. SR 13179 has no effect on the expression of MMP-2 or MT1-MMP protein or mRNA, but instead increased protein levels of TIMP-2 by 5-fold after 48 h. SR 13179 has potent antitumor activity in several tumor cell lines regardless of their hormone receptor, p53 or multi-drug resistance status. SR 13179 also possesses potent anti-angiogenic activity in the chorioallantoic membrane (CAM) assay. Since TIMP-2 is a multifunctional molecule with inhibitory effects on tumor growth, metastasis and angiogenesis, it is likely that the increase in TIMP-2 protein levels by SR 13179 plays a central role in the anti-tumor, anti-invasive and anti-angiogenic activity of this novel small molecule. These activities can be mediated through MMP-dependent as well as MMP-independent growth signaling pathways. The results of these mechanistic studies with SR 13179 will be presented. These studies were partly supported by the DoD Breast Cancer Research Program grant (DAMD 17-03-1-0587 to NZ).

  • American Association for Cancer Research
Previous
Back to top
Cancer Research: 65 (9 Supplement)
May 2005
Volume 65, Issue 9 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
A novel small molecule, SR 13179, decreases gelatinase activity in breast carcinoma cells through induction of TIMP-2 protein: A possible mechanism for its anti-invasive and anti-tumor activity
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
A novel small molecule, SR 13179, decreases gelatinase activity in breast carcinoma cells through induction of TIMP-2 protein: A possible mechanism for its anti-invasive and anti-tumor activity
Nahid Waleh, Wan-Ru Chao, Brian Murphy and Nurulain Zaveri
Cancer Res May 1 2005 (65) (9 Supplement) 549;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
A novel small molecule, SR 13179, decreases gelatinase activity in breast carcinoma cells through induction of TIMP-2 protein: A possible mechanism for its anti-invasive and anti-tumor activity
Nahid Waleh, Wan-Ru Chao, Brian Murphy and Nurulain Zaveri
Cancer Res May 1 2005 (65) (9 Supplement) 549;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Suppression of cancer cell proliferation and invasion by Big1, a novel retinoic acid receptor-beta2 induced gene through binding to and inhibition of RhoA
  • Novel molecular actions of the anti-obesity drug Orlistat (Xenical™) in cancer cells: Blockade of cell cycle progression, promotion of apoptotic cell death, PEA3-mediated transcriptional repression of Her-2/neu (erbB-2) oncogene, and sensitization to trastuzumab (Herceptin™)-induced cell growth inhibition
  • CD26 mediates cell adhesion to extracellular matrix proteins through p38-dependent phosphorylation of integrin beta1 in T- anaplastic large cell lymphoma Karpas 299
Show more Experimental and Molecular Therapeutics 20: Identification of Molecular Targets 1
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement